Skip to content

Ground-breaking Alzheimers blood test

At the European Academy of Neurology Congress in Helsinki, researchers unveiled a ground breaking blood test that could revolutionize Alzheimer’s disease management by identifying

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Donanemab and Lecanemab rejected for the NHS

Two innovative Alzheimer’s drugs, Donanemab and Lecanemab, have been rejected by the NHS due to their exorbitant cost and limited impact. These are the first treatments to slow the disease, potentially extending

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here